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Abstract
Background: Pregnancy is a process associated with various metabolic and hormonal
changes, and polycystic ovary syndrome (PCOS) can affect this process.
Objective: This study aimed to evaluate and compare the maternal and neonatal
outcomes among pregnant women with different polycystic ovary syndrome
phenotypes.
Materials and Methods: In this cross-sectional study, 200 pregnant women with
PCOS according to the 2003 ESHRE/ASRM criteria were categorized into four
phenotype groups (A-D). The maternal outcomes include gestational diabetes mellitus,
pregnancy-induced hypertension, premature rupture of membranes, preterm labor,
small-for-gestational age birth, intrauterine growth restriction, intrauterine mortality,
preeclampsia, abortion, amniotic fluid disorders, delivery method, and cause of
cesarean section were studied between groups. Additionally, neonatal outcomes
such as neonatal weight, neonatal recovery, 5-min Apgar score, neonatal icter, the
need for NICU admission, the cause of hospitalization, and infant mortality rate were
investigated and compared among the groups.
Results:According to the results, phenotype D (37%) was themost common phenotype
among the participants. The risk of gestational diabetes was more common in
phenotype A than in the other phenotypes, whereas pregnancy-induced hypertension
was most common in phenotype B. No significant differences were observed in the
neonatal complications among the PCOS phenotypes.
Conclusion: Considering the higher risk of gestational diabetes mellitus and
pregnancy-induced hypertension in PCOS phenotypes A and B, women with these
phenotypes need more precise prenatal care.
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1. Introduction
Pregnancy is a process associated with various
metabolic and hormonal changes, and the onset
of polycystic ovary syndrome (PCOS) can affect
this process (1). According to the World Health
Organization (2012), women with PCOS are at risk
of prenatal complications during pregnancy as
well as most pregnancy pathologies, including
gestational diabetes mellitus, glucose tolerance
disorders, pregnancy-induced hypertension,
preeclampsia, fetal growth restriction, preterm
delivery, and small for gestational age (2). Previous
studies have also reported an increased risk of
morbidity and hospitalization in the neonatal
intensive care unit in pregnant women with PCOS
(3, 4). Some reports have suggested an increase
in the incidence of spontaneous abortion and
preterm delivery for these women compared
with healthy pregnant women (1, 5-8). Due to
the importance of pregnancy in these women,
especially those with infertility, as well as their
phenotypic differences and the limited information
available on their pregnancy outcomes, this
study was designed to evaluate and compare the
maternal and neonatal outcomes among pregnant
women with different PCOS phenotypes.
2. Materials and Methods
This cross-sectional study was performed on
200 pregnant women under 40 yr old with a history
of PCOS according to the ESHRE/ASRM criteria
(Rotterdam) (9) who were referred to the obstetrics
and gynecology department of Shahid Sadoughi
Hospital, Yazd, Iran, between 2017 and 2018.
The exclusion criteria included uterine
abnormalities, other causes of hyperandrogenism
such as congenital adrenal hyperplasia; malignant
ovarian tumors; androgen-secreting tumors;
Cushing disease; hyperprolactinemia; chronic
diseases such as lupus, kidney, and liver disease;
diabetes mellitus; and cigarette, drug, and alcohol
use.
Based on the Rotterdam criteria (10), the
participants were categorized into four PCOS
phenotype groups from the beginning of the
prenatal period to delivery:
Type A: Having symptoms of hyperandrogenism,
chronic ovulation, and polycystic ovaries
Type B: Having symptoms of hyperandrogenism
and chronic anovulation
Type C: Having symptoms of hyperandrogenism
and polycystic ovaries
Type D: Having symptoms of chronic ovulation
and polycystic ovaries
The participants ’basic characteristics, e.g., age,
gravidity, parity, history of abortion and infertility,
occupation, history of surgery, use of assisted
reproductive techniques, and gestational age, also
their maternal outcomes, e.g., gestational diabetes
mellitus and hypertension, premature rupture of
membranes, preterm labor, small for gestational
age, intrauterine growth restriction, intrauterine
fetal death, preeclampsia, abortion, amniotic fluid
disorders, delivery method, and cause of cesarean
section, were recorded. Neonatal information,
including weight, neonatal recovery, 5-min Apgar
score, neonatal icter, the need for admission, the
cause of hospitalization, and the infant mortality
rate were recorded in a neonatal complications
questionnaire.
2.1. Ethical consideration
The Ethics Committee of the Shahid Sadoughi
University of Medical Sciences, Yazd, Iran,
approved the proposal of this research (Code:
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IR.SSU.MEDICINE.REC.1397.114). Written informed
consent was obtained from all participants.
2.2. Statistical analysis
Considering a 95% confidence interval, a power
of 80%, the frequency of phenotype B (16%) in the
participants as the lowest frequency, and a 10%
error, a sample size of 200 was determined using
the following formula:
𝑁 =
(𝑍1− 𝛼2 + 𝑍1−𝛽)
2 × [𝑃 (1 − 𝑃 )]
𝑑2
All data were analyzed using the Statistical
Package for the Social Sciences (SPSS) software
(SPSS Inc., Chicago, Illinois, U.S.A), version 17.0. For
the quantitative and qualitative variables, the mean
± standard deviation and the frequency and rate,
respectively, were measured and investigated via
the Pearson correlation coefficient and Spearman’s
correlation coefficient tests. A p-value <0.05 was
considered significant.
3. Results
In this study, 200 pregnant women with PCOS
were studied into four phenotype groups (A-D).
Two participants from group D were excluded
due to unintended pregnancy and the use of
abortion induction. Thus, the final study population
consisted of 198 pregnant women with a mean age
of 29.2 ± 7.7 year. Group D with 37% and group B
with 14% had the highest and lowest frequencies,
respectively (Table I).
The participants’ demographic characteristics
are presented in Table II. There was no difference
in maternal age (p = 0.32) among the four
groups. In group A, the history of abortion (48.9%)
and infertility (51.1%) was higher than in the
other groups; this difference was significant for
the infertility history (p = 0.007) (Table II). The
miscarriage rate did not differ statistically in study
groups. 37 pregnancies resulted in miscarriage.
Maternal outcomes was examined only in cases of
ongoing pregnancy.
Gestational diabetes mellitus (GDM) was
evaluated via two methods: fasting blood sugar
(FBS) measurement and an oral glucose tolerance
test (OGTT). Our results showed that the rate of
GDM was significantly different among the four
groups. In addition, group A had a higher abnormal
OGTT than the other groups. The highest GDM
was associated with phenotype A and the lowest
with phenotype D. The FBS comparison among
the study groups showed a statistically significant
difference between groups (p = 0.035).
Groups B (36.8%) andA (28.57%) had the highest
blood pressure levels among the groups (p =
0.001), whereas group C had the lowest level
of gestational hypertension (0%). The groups did
not differ significantly in terms of preeclampsia
(p = 0.08); however, the rate of preeclampsia
was higher in groups B and A than in the
other groups. The groups were similar regarding
the other maternal outcomes, including amniotic
fluid, abortion, perinatal outcomes, term, and
preterm deliveries, delivery type, and pregnancy
termination method. One case of stillbirth was
observed in group A, and, overall, the rate of
cesarean section in all groups was higher than
normal vaginal delivery (Table III).
11 cases of multiple pregnancies were reported
that did not differ statistically between groups
(Table II). Neonatal outcome was evaluted only
on single pregnancies. According to the obtained
results, there was no significant difference in the
neonatal outcomes among the groups, including
the 5-min Apgar score, birth weight, neonatal icter,
and frequency of anomalies in newborns (Table IV).
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Table I. Frequency distribution of PCOS phenotypes in the study participants (n = 198)





Table II. Comparison of demographic characteristics among the study groups
Variables Group A (n = 45) Group B (n = 27) Group C (n = 52) Group D (n = 74) P-value
Age (mean ± SD) (year) 28.7 ± 5.2 28.7 ± 2.9 28.5 ± 4.9 30 ± 4.7 0.32∗
History of abortion n (%) 22 (48.9) 11 (40.7) 12 (23.1) 26 (35.9) 0.63∗∗
History of infertility n (%) ** 23 (51.1) 6 (22.2) 13 (25) 18 (24.3) 0.007∗∗
Abortion 10 (22.22) 8 (29.62) 8 (15.38) 11 (14.86) 0.156**
Pregnancy method n (%)
Natural 34 (75.6) 23 (85.2) 43 (82.7) 62 (83.8)
Medication 8 (17.8) 4 (14.8) 7 (13.5) 8 (10.8)
IUI 0 (0) 0 (0) 2 (3.8) 1 (1.4)
ART 3 (6.7) 0 (0) 0 (0) 3 (4.1)
0.44∗∗
Type of pregnancy n (%)
Singleton 31/35 (88.57) 19/19 (100.00) 41/44 (93.2) 59/63 (93.2)
Twin 3 (8.6) 0 (0.00) 3 (6.8.) 4 (6.3)
Triplet 1 (2.2) 0 (0.00) 0 (0) 0 (0)
0.50∗∗
*ANOVA test, **Chi-squar test
Table III. Comparison of maternal outcomes in study groups ongoing pregnancies according to phenotype
Maternal outcomes /
Ongoing pregnancy
Group A (n = 35) Group B (n = 19) Group C (n = 44) Group D (n = 63) P-value
FBS (mean±SD) 93.65 ± 15.23 89.21 ± 9.80 86.38 ± 12.23 87.31 ± 9.51 0. 035 *
Abnormal GTT n (%) 18/35 (51.42) 6/19 (31.57) 13/44 (29.54) 13/63 (20.63) 0.018**
GDM n (%) 18/35 (51.42) 6/19 (31.57) 14/44 (31.81) 14/63 (22.22) 0.032**
Gestational hypertension n (%) 10/35 (28.57) 7/19 (36.84) 0/44 (0) 9/63 (14.28) <0.001**
Preeclampsia n (%) 6/35 (17.1) 5/19 (26.3) 3/44 (6.8) 5/63 (7.9) 0.08**
Amniotic fluid n (%) 0.62**
Normal 32/35 (91.4) 17/19(89.5) 41/44 (93.2) 60/63 (95.23)
Oligohydramnios 1/35 (2.9) 1/19 (5.3) 3/44 (6.8) 2/63 (3.17)
Polyhydramnios 2/35 (5.7) 1/19(5.3) 0/44 (0) 1/63 (1.58)
PROM n (%) 3/35 (8.6) 2/19 (10.5) 1/44 (2.3) 4/63 (6.3) 0.54**
Perinatal outcomes n (%)
Live births 34/35 (97.1) 19/19 (100) 44/44 (100) 63/63 (100)
Still birth 1/35 (2.9) 0/19 (0) 0/44 (0) 0/63 (0)
0.30**
Type of delivery n (%)
Term 22/35 (62.85) 12/19 (63.15) 37/44 (84.09) 48/63 (76.19)
Preterm 13/35 (37.14 7/19 (36.84) 7/44 (15.90) 15/63 (23.80)
0.08**
Pregnancy termination method n (%)
NVD 14/35 (40) 7/19 (36.8) 21/44 (47.7) 30/63(47.61)
Cesarean section 21/35 (60) 12/19 (63.2) 23/44 (52.3) 33/63 (52.38)
0.76**
FBS: Fasting blood sugar; GTT: Glucose tolerance test; GDM: Gestational diabetes mellitus; PROM: Premature rupture of
membranes; NVD: Normal vaginal delivery.
*ANOVA test; **Chi-square test
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Table IV. Neonatal outcomes in pregnant women with different PCOS phenotypes
Variables/Single pregnancy Group A (n = 30) Group B (n = 19) Group C (n = 41) Group D (n = 59) P-value*
5-min apgar score (mean±SD) 9.63 ± 0.88 9.57 ± 1.01 9.63 ± 0.86 9.83 ± 0.56 0.463
Neonatal birth weight
AGA 26/30 (86.66) 16/19 (84.21) 35/41 (85.36) 54/59 (91.52)
Severe IUGR 2/30 (6.66) 1/19 (5.26) 3/41 (7.31) 0/59 (0)
SGA 0/30 (0) 1/19(5.26) 1/41 (2.43) 1/59 (1.69)
Macrosomia 2/30 (6.66) 1/19 (5.26) 2/41 (4.87) 4/59 (6.78)
0.733
Neonatal icter n (%) 17/30 (56.66) 8/19 (42.10) 14/41 (34.14) 30/59 (50.84) 0.225
Neonatal condition n (%)
Good 25/30 (6.93) 13/19 (68.42) 35/41(85.36) 52/59 (88.13)
NICU admission 5/30 (16.66) 5/19 (26.31) 6/41 (14.63) 7/59 (11.86)
Neonatal death 0/30(0) 1/19 (5.26) 0/41 (0) 0/59 (0)
0.147
Anomalies n (%) 0/30 (0) 1/19 (5.26) 1/41 (2.43) 1/59 (1.69) 0.637
Severe IUGR: a fetal weight below the third percentile for gestational age as determined through an ultrasound.
SGA (small gestational age): a fetal weight between the 3rd and 10th percentiles for gestational age as determined through an
ultrasound. *Chi-square test
4. Discussion
In this study, the maternal and neonatal
outcomes of different PCOS phenotypes
were compared. According to our results,
phenotype D (37%) and phenotype B (14%)
had the highest and lowest frequencies in
the study population, respectively. However,
Vaggopoulos and colleagues, in a study on 266
women with PCOS showed that phenotype A
was the most frequent (11). Also, Baldani and
co-workers obtained similar results in Croatia
(12).
In the current research, the abortion rate
in phenotypes B and A was higher than in
the other phenotypes, but this difference was
not statistically significant. According to previous
studies, the risk of abortion in women with
PCOS is three times higher than in healthy
pregnant women (13). Similarly, Palomba and
colleagues demonstrated that the abortion rate
in phenotype A is significantly higher than in
other phenotypes (14). However, Jakubowicz et al.
did not report any differences among the PCOS
phenotypes regarding the abortion rate (15).
Perhaps it would be possible to achieve more
reliable results on the abortion rate in these
patients with a higher sample size of different
PCOS phenotypes.
Our results also showed that the rate of GDM
in women with PCOS significantly differed among
the four phenotypic groups, and the highest GDM
level was observed in group A. According to
the logistic regression analysis, phenotypes A
and B had a higher chance of having a higher
mean of fasting blood glucose, OGTT, and GDM
compared with phenotypes C and D. In Palomba
and co-workers’ study, GDM was more frequent
in phenotypes A and C (14), whereas, , another
in 2015 showed that the incidence of GDM in
phenotypes A and B was higher than in the other
phenotypes (16).
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Furthermore, our study results showed that
phenotypes B and A had the highest levels of
pregnancy-induced hypertension. A previous
study demonstrated that the incidence of
maternal and neonatal complications in pregnant
women with PCOS was higher than in the
control group, especially in the phenotypes with
oligo-menorrhea and hyperandrogenism. Also,
pregnancy-induced hypertension in phenotypes
A and B was reported more often than in
other phenotypes (17). Moreover, Kollman and
colleagues divided PCOS phenotypes into oligo-
ovulatory (A, B) and ovulatory (C, D) groups and
reported more pregnancy-induced hypertension
in groups A and B compared with the other two
groups (16).
In the present study, one intrauterine fatal
death was observed in group A, which was not
statistically different from the other groups. In
normal pregnancies, this rate is predicted by
mortality in the uterus. Our results were consistent
with other studies (18), which reported that PCOS
phenotypes have no effect on stillbirths.
Another study in 2013 reported that maternal
complications such as preeclampsia in pregnant
women with PCOS are significantly higher than in
healthy pregnant women (19). In Palomba’s study,
the incidence of preeclampsia was highest in
phenotypes A and B (20). According to Kollmann
and others’ results, the incidence of preeclampsia
in oligo-ovulatory phenotypes is significantly
higher than in others (16). In the current research,
the incidence of preeclampsia in phenotypes B
and A was highest; but, no significant difference
regarding preeclampsia was observed among
the studied groups. In the logistic regression
test, phenotype B had a higher chance of
preeclampsia. There were no differences in the
other adverse outcomes of pregnancy such as
amniotic fluid disorders, premature rupture of
membranes, adverse perinatal outcomes, and
preterm deliveries between PCOS phenotypic
groups, which was consistent with Kollmann
and Palomba’s studies (16, 17). Moreover, no
significant difference was found in the neonatal
outcomes investigated among the different
phenotypes of PCOS, including the 5-min Apgar
score, birthweight, neonatal anomalies, and NICU
admission. similar to Kollmann et al. results (16).
5. Conclusion
Considering the higher risk of GDM and
pregnancy-induced hypertension in PCOS
phenotypes A and B, women with these
phenotypes require more precise prenatal care.
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